DocDollars

Aerie Pharmaceuticals, Inc.

NC · United States · Reporting entity ID 100000216803

Total reported 2019–2025
$12.4M
#433 of 2,960 reporting companies — 0% of all reported industry payments
$7.54M in general payments across 46,542 records, plus $4.86M in research funding across 500 records.

How it breaks down

General payments $7,540,061
Research funding $4,863,246

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Aerie Pharmaceuticals, Inc. reported $12.4M to US doctors and teaching hospitals from 2019 to 2025, ranking #433 of 2,960 reporting companies. 39% of that was research funding and 61% general payments such as consulting, speaking, food and travel. 46,542 general payment records and 500 research records were filed.

Common questions about Aerie Pharmaceuticals, Inc.

How much has Aerie Pharmaceuticals, Inc. paid US doctors?

Aerie Pharmaceuticals, Inc. reported $12,403,307 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $7,540,061 in general payments, $4,863,246 in research funding.

How does Aerie Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #433 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Aerie Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.